Our data suggest that targeting both CT-L and T-L activities can overcome Btz resistance, and therefore a dual inhibitor of the β2 and β5 subunits may be a new treatment option for patients with Btz/Cfz-resistant MM cells, who have poor treatment options for this incurable disease. The gene discussed is TBXT; the disease is Miyoshi myopathy.